Literature DB >> 10690844

HSV-1--induced acute retinal necrosis syndrome presenting with severe inflammatory orbitopathy, proptosis, and optic nerve involvement.

N R Tornerup1, A Fomsgaard, N V Nielsen.   

Abstract

OBJECTIVE: To present a unique case in which orbital inflammation, proptosis, and optic neuritis were the initial symptoms of acute retinal necrosis (ARN). The clinical presentation of ARN, as well as the currently recommended diagnostic procedures and guidelines for medical treatment of ARN, are summarized.
DESIGN: Interventional case report. TESTING: Polymerase chain reaction (PCR) techniques were made on the vitreous for cytomegalovirus, Epstein-Barr virus, herpes simplex virus (HSV), varicella zoster virus, and toxoplasmosis. A full laboratory evaluation was made together with HLA-typing and serologic tests measuring convalescent titers for HSV and other micro-organisms. Magnetic resonance imaging scan, computed tomography (CT) scan, and fluorescein angiographic examination were performed. The patient was treated with acyclovir and oral prednisone. MAIN OUTCOME MEASURES: The patient was evaluated for initial and final visual acuity and for degree of proptosis, periocular edema, and vitreitis.
RESULTS: The first symptoms and signs of ARN were eye pain, headache, proptosis, and a swollen optic nerve on CT scan. Other than increased C-reactive protein, all blood samples were normal. PCR was positive for HSV-type I in two separate vitreous biopsies. The patient had the strongly ARN-related specificity HLA-DQ7.
CONCLUSIONS: This is the first report of HSV-induced ARN presenting with inflammatory orbitopathy and optic neuritis. Polymerase chain reaction for HSV-1 was positive more than 4 weeks after debut of symptoms, which is a new finding. The combination of severe vitreitis and retinal whitening, with or without proptosis, should alert the clinician to the possibility of herpes infection and treatment with intravenous acyclovir started promptly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690844     DOI: 10.1016/s0161-6420(99)00053-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Catastrophic acute retinal necrosis syndrome associated with diffuse orbital cellulitis: a case report.

Authors:  Olivier Rozenbaum; Flore Rozenberg; Frederic Charlotte; Bahram Bodaghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-21       Impact factor: 3.117

2.  Good visual outcome in an immunocompromised patient with bilateral acute retinal necrosis syndrome: A case report.

Authors:  Ricardo E Marrocos de Aragão; Ieda M A Barreira; Barbara L A Arrais; Leidiane A Pereira; Carine S Ramos
Journal:  Saudi J Ophthalmol       Date:  2013-11-18

3.  Restrictive orbital myofibroblastic sarcoma in a cat--cross-sectional imaging (MRI & CT) appearance, treatment, and outcome.

Authors:  Sara M Thomasy; Derek D Cissell; Boaz Arzi; Jose G Vilches-Moure; Winnie Y Lo; Erik R Wisner; Richard R Dubielzig; David J Maggs
Journal:  Vet Ophthalmol       Date:  2013-01-03       Impact factor: 1.644

4.  Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK.

Authors:  M N Muthiah; M Michaelides; C S Child; S M Mitchell
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

5.  Orbital inflammation developing from epidemic keratoconjunctivitis in an adult.

Authors:  Sung In Kim; Kyeong Wook Lee
Journal:  Case Rep Ophthalmol       Date:  2013-08-15

6.  Concurrent acute retinal necrosis and orbital inflammation: Report of 2 cases.

Authors:  Swarup S Swaminathan; Nicolas A Yannuzzi; Andrew J Rong; Ashley M Crane; Thomas A Albini
Journal:  Am J Ophthalmol Case Rep       Date:  2019-02-13

7.  Idiopathic sclerosing orbital pseudotumor in seven cats.

Authors:  F Mark Billson; Tammy Miller-Michau; John R B Mould; Michael G Davidson
Journal:  Vet Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 1.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.